Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

sanofi-aventis deutschland gmbh - docetaxel (docetaxel trihydrate) - concentrate for solution for infusion - 20mg/ml

European Union - English - EMA (European Medicines Agency)

sanofi-aventis deutschland gmbh - leflunomide - arthritis, rheumatoid; arthritis, psoriatic - immunosuppressants - leflunomide is indicated for the treatment of adult patients with:active rheumatoid arthritis as a 'disease-modifying antirheumatic drug' (dmard);active psoriatic arthritis.recent or concurrent treatment with hepatotoxic or haematotoxic dmards (e.g. methotrexate) may result in an increased risk of serious adverse reactions; therefore, the initiation of leflunomide treatment has to be carefully considered regarding these benefit / risk aspects.moreover, switching from leflunomide to another dmard without following the washout procedure may also increase the risk of serious adverse reactions even for a long time after the switching.

European Union - English - EMA (European Medicines Agency)

sanofi-aventis deutschland gmbh - insulin glargine - diabetes mellitus - drugs used in diabetes - treatment of diabetes mellitus in adults, adolescents and children aged two years and above

European Union - English - EMA (European Medicines Agency)

sanofi-aventis deutschland gmbh - insulin glargine - diabetes mellitus - drugs used in diabetes - treatment of diabetes mellitus in adults, adolescents and children from the age of 6 years.,

European Union - English - EMA (European Medicines Agency)

sanofi-aventis - rimonabant - obesity - antiobesity preparations, excl. diet products - as an adjunct to diet and exercise for the treatment of obese patients (bmi 30 kg/m2), or overweight patients (bmi 27 kg/m2) with associated risk factor(s), such as type 2 diabetes or dyslipidaemia (see section 5.1).

European Union - English - EMA (European Medicines Agency)

sanofi-aventis - rimonabant - obesity - antiobesity preparations, excl. diet products - as an adjunct to diet and exercise for the treatment of obese patients (bmi 30 kg/m2), or overweight patients (bmi 27 kg/m2) with associated risk factor(s), such as type 2 diabetes or dyslipidaemia (see section 5.1).

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

sanofi-aventis deutschland gmbh - levofloxacin (levofloxacin hemihydrate) - solution for infusion - 5mg/ml

Singapore - English - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - alirocumab - injection, solution - alirocumab 150mg

Singapore - English - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - alirocumab - injection, solution - alirocumab 75mg

Israel - English - Ministry of Health

sanofi israel ltd - insulin glargine - solution for injection - insulin glargine 300 u/ml - insulin glargine - treatment of diabetes mellitus in adults, adolescents and children from the age of 6 years .